Skip To Main Content
Zeynep Ülkü Gün on Muck Rack

Zeynep Ülkü Gün

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zeynep Ülkü

Contact Zeynep Ülkü, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The safety profile of favipiravir in COVID‐19 patients with severe renal impairment

|
By Selim Gök, Ömer Faruk Bahçecioğlu, Mefküre Durmuş, Zeynep Ülkü Gün
| Wiley Online Library Verified
What’s known In COVID-19 patients, chronic renal disease is linked to an increase in morbidity and mortality. Despite the lack of safety data for favipiravir in patients with renal failure, the emergence of COVID-19 justifies its usage in this population. Favipiravir-related side effects (eg, hepatocellular injury) are well known, although the risk factors that lead to these side effects are unknown.
Open in Who Shared Issue with article?
See all 1 articles